Synovial sarcoma is a rare, aggressive cancer with limited treatment options. Tecelra, the first T-cell receptor (TCR) gene therapy approved in the U.S., marks a major breakthrough by engineering patients’ T-cells to target tumor antigens. It has shown promising responses in advanced cases, offering new hope and advancing precision cancer therapy.

A sarcoma diagnosis often brings urgent treatment decisions that may permanently affect future options. This article outlines when a structured U.S. second opinion may be appropriate, what it evaluates, and how patients can obtain independent expert review when access to major cancer centers is delayed. The goal is clarity before irreversible steps are taken.